Erectile dysfunction and testosterone deficiency as cardiovascular risk factors?
Corresponding Author
Geoffrey Hackett
Good Hope Hospital, Sutton Coldfield, UK
Correspondence
Geoffrey Hackett, Good Hope Hospital, Sutton Coldfield, UK.
Email: [email protected]
Search for more papers by this authorMichael Kirby
The Centre for Research in Primary and Community Care, University of Hertfordshire, Hatfield, UK
The Prostate Centre, London, UK
Search for more papers by this authorCorresponding Author
Geoffrey Hackett
Good Hope Hospital, Sutton Coldfield, UK
Correspondence
Geoffrey Hackett, Good Hope Hospital, Sutton Coldfield, UK.
Email: [email protected]
Search for more papers by this authorMichael Kirby
The Centre for Research in Primary and Community Care, University of Hertfordshire, Hatfield, UK
The Prostate Centre, London, UK
Search for more papers by this authorSummary
Graham Jackson introduced the concept that erectile dysfunction was a marker for undiagnosed cardiovascular disease and future events. Unfortunately this had had modest impact on CVD management as ED is not incorporated into current risk calculators. In this paper, we examine recent evidence as to whether ED should be upgraded to a risk factor, especially with the high predictive value in younger men. In the Princeton 3 guidelines, he recognised the important impact of testosterone deficiency (TD) on all-cause and cardiovascular mortality. Recent evidence suggests that testosterone therapy to target levels and for sufficient duration, reduces cardiovascular events. In this paper, we also produce a case for testosterone deficiency to be considered as an independent risk factor. The evidence for inclusion of both ED and TD may now be stronger than accepted risk factors and have the advantages of being easily assessed, being quantitative, symptomatic and clinically relevant, especially in younger men.
REFERENCES
- 1Wald NJ, Hackshaw AK, Frost CD. When can a risk factor be used as a worthwhile screening test? BMJ. 1999; 319: 1562-1565.
- 2Li G, Baker SP, Qiang Y, Grabowski JG, McCarthy ML. Driving-while-intoxicated history as a risk marker for general aviation pilots. Accid Anal Prev. 2005; 37: 179-84.
- 3McFadden KL. Driving while intoxicated (DWI) convictions and job-related flying performance – A study of commercial air safety. J Oper Res Soc. 1998; 49: 28-32.
- 4Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease: 6-year follow-up experience. The framingham study. Ann Intern Med. 1961; 55: 33-50.
- 5Yusuf S, Hawken S, Ounpuu S. Dans T, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364: 937-952.
- 6Hippisley-Cox J, Coupland D, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008; 336: 1475-1482.
- 7 Joint British Societies for Prevention of Cardiovascular disease. http://www.jbs3risk.com/. Accessed January 3, 2018.
- 8Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2016: 37: 2315-2381. https://doi.org/10.1093/eurheartj/ehw10
- 9Nehra A, Jackson G, Miner M, et al. The Princeton III Consensus recommendations for the man-agement of erectile dysfunction and cardiovascular disease. Mayo Clin Proc. 2012; 87: 766-78.
- 10Jackson G, Nehra A, Miner M, et al. The assessment of vascular risk in men with erectile dys-function: the role of the cardiologist and general physician. Int J Clin Pract. 2013; 67: 1163-72.
- 11Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes. 2013; 6: 99-109.
- 12Gazzaruso C, Solerte SB, Pujia A, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease: a potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol. 2008; 51: 2040-2044.
- 13Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. Eur Heart J. 2006 Nov; 27: 2632-9.
- 14Inman BA, Sauver JL, Jacobson DJ, et al. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc. 2009; 84: 108-13.
- 15Banks E, Joshy G, Abhayaratna WP. Erectile dysfunction severity as a risk marker for cardiovascular disease hospitalisation and all-cause mortality – A prospective study. PLoS Med. 2013; 10: e1001372.
- 16Ma RC, So WY, Yang X, et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol. 2008; 51: 2045-2050.
- 17Home P, Mant J, Diaz J, Turner C, on behalf of the Guideline Development Group. Management of type 2 diabetes: summary of updated NICE guidance. BMJ. 2008; 336: 1306-1308.
- 18 Qualities and Outcomes Framework 2016-17. https://digital.nhs.uk/catalogue/PUB30124. Accessed January 3, 2018.
- 19Miner M, Seftel AD, Nehra A, et al. Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes. Am Heart J. 2012; 164: 21-25.
- 20Wing RR, Rosen RC, Fava JL, et al. Effects of weight loss intervention on erectile function in older men with type 2diabetes in the Look AHEAD trial. J Sex Med. 2010; 7: 156-65.
- 21Gupta BP, Murad MH, Clifton MM, Prokop L, Nehra A, Kopecky SL. The effect of Lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and me-ta-analysis. Arch Intern Med. 2011; 171: 1797-803.
- 22Smith GD, Frankel S, Yarnell J. Sex and death: are they related? Findings from the Caerphilly cohort study. BMJ. 1997; 315: 1641-5.
- 23Hall SA, Shackleton R, Rosen RC, Araujo AB. Sexual activity, erectile dysfunction and incident cardiovascular events. Am J Cardiol. 2010; 105: 192-7.
- 24Corona G, Rastrelli M, Monami M, et al. Frequency of sexual activity and cardiovascular risk in subjects with erectile dysfunction: cross-sectional and longitudinal analyses. Andrology. 2013; 1: 864-871.
- 25Anderson S, Hutchings DC, Woodward M, et al. Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality. Heart. 2016; 102: 1750-1756.
- 26Andersson DP, Lagerros YT, Grotta A, Bellocco R, Lehtihet M, Holtzmann MJ. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017; 103: 1264-1270. https://doi.org/10.1136/heartjnl-2016-310746.
- 27Hackett G, Heald AH, Sinclair A, Jones PW, Strange RC, Ramachandran S. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 3 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. Int J Clin Pract. 2016; 70: 244-53.
- 28Rosano GM, Aversa A, Vitalea C, Fabbric A, Finia M, Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol. 2005; 47: 214-22.
- 29Guazzi M, Vicenzi M, Arena R, Guazzi MD. PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure results of a 1-year, prospective, randomized, placebo-controlled study. Circ Heart Failure. 2011; 4: 8-17.
- 30Afsar B, Ortiz A, Covic A. Phosphodiesterase type 5 inhibitors and kidney disease. Int Urol Nephrol. 2015; 47: 1521-8.
- 31Peak TC, Richman A, Gur S, Yafi FA, Hellstrom WJ. The role of PDE5 inhibitors and the NO/cGMP pathway in cancer sex. Med Rev. 2016; 4: 74-84.
- 32Pye SR, Huhtaniemi IT, Finn JD, et al. Late-onset hypogonadism and mortality in aging men. JCEM. 2013; 99: 1357-1366.
- 33Ruige JB, Mahmoud AM, De Bacquer D, Kaufman JM. Endogenous testosterone and cardiovascular disease in healthy men: a meta-analysis. Heart. 2011; 97: 870-5.
- 34Daka P, Langer RD, Larsson CA. Low concentrations of serum testosterone predicts acute myocardial infarction in men with type 2 diabetes mellitus. BMC Endocr Disorder. 2015; 15: 1-12.
- 35Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96: 3007-19.
- 36Haring R, Volzke HV, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J. 2010; 31: 1494-501.
- 37Corona G, Rastrelli G, Maggi M. Diagnosis and treatment of late onset hypogonadism: systematic review and meta-analysis of TRT outcomes. Best Pract Res Clin Endocrinol Metab. 2013; 27: 557-79.
- 38Oh J-Y, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002; 25: 55-60.
- 39Haffner SM, Shaten J, Stern MP, Smith GD, Kuller L. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996; 143: 889-897.
- 40Holmboe S, Jensen T, Linneberg A, et al. Low testosterone: a risk marker rather than a risk factor for type 2 diabetes. JCEM. 2016; 101: 3180-3190.
- 41Tajar A, Huhtaniemi IT, O'Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European Male Aging Study (EMAS). J Clin Endocrinol Metab. 2012 May; 97: 1508-16.
- 42Muraleedaran V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013 Oct 21; 169: 725-33.
- 43Shores M, Smith NL, Forsberg CW, Anawalt BD, Marsumoto AM. Testosterone treatment and mortality in men with low testosterone. J Clin Endocrin Metab. 2012; 97: 2050-2058.
- 44Anderson JL, May HT, Lappe DL, et al. Impact of testosterone replacement therapy on myocardial infarction, stroke, and death in men with low testosterone concentrations in an integrated health care system. Am J Cardiol. 2016; 117: 794-799.
- 45Budoff MJ, Ellenberg SE, Lewis CE, et al. Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA. 2017; 317: 708-716.
- 46Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015; 36: 2706-15.
- 47Wallis CJD, Lo K, Lee Y, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes Endocrinol.June 2016; 4: 498-506.
- 48Fui MNT, Prendergast LA, Dupuis P, et al. Effects of testosterone treatment on body fat and lean mass in obese men on a hypocaloric diet: a randomised controlled trial. BMC Med. 2016; 14: 153.
- 49Saad F, Rohrig G, vonHaehling S, Traish A. Testosterone deficiency and testosterone treatment in older men. Gerontology. 2016; 63: 144-156.
- 50Kloner RA, Carson C III, Dobs A, Kopecky S, Mohler ER III. Testosterone and cardiovascular disease. J Am Coll Cardiol. 2016; 67: 545-57.
- 51Araujo AB, Hall SA, Ganz P, et al. Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the framingham risk score? J Am Coll Cardiol. 2010; 55: 350-356.
- 52Billups KL, Miner MM, Wierzbicki AS, Jackson G. Gender-based cardiometabolic risk evaluation in minority and non-minority men grading the evidence of non-traditional determinants of cardiovascular risk. IJCP. 2011; 65: 107-229.
- 53Shah NP, Cainzos-Achirica M, Feldman DI, Miner M, et al. Cardiovascular disease prevention in men with vascular erectile dysfunction: the view of the preventive cardiologist. Am J Med. 2016; 129: 251-259.
- 54Jackson G. Erectile dysfunction and asymptomatic coronary artery disease: frequently detected by computed tomography coronary angiography but not by exercise electrocardiography. Int J Clin Pract. 2013; 67: 1159-1162.